CCR2 and Patent ductus arteriosus: In 2 different clinical trials, CCR2 antagonists have been combined with chemotherapy (58, 59) in an attempt to overcome chemoresistance in pancreatic cancer patients, yet to our knowledge, CCR2 inhibition in concert with immune therapy has not yet been trialed in PDA.